LPL Financial
ANIK icon

LPL Financial’s Anika Therapeutics ANIK Stock Holding History

LPL Financial’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-5,378
Closed -$207K – 3110
2015
Q4 		$207K Buy
+5,378
New +$206K ﹤0.01% 2796

Other funds holding ANIK

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
AAM
AMI Asset Management Los Angeles, California $1.74B AUM 26.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

LPL Financial's ANIK Position: Q1 2016 in Review

LPL Financial sold out of Anika Therapeutics (ANIK) in Q1 2016, closing a stake of 5,378 shares — an estimated $207K sold.

LPL Financial first reported a position in ANIK in Q4 2015 and held it in 1 quarter. The position peaked at $207K in Q4 2015. 162 funds tracked by Wall St. Rank hold ANIK as of Q1 2016.

  • LPL Financial reported no remaining Anika Therapeutics position as of Q1 2016 after selling out during the quarter.
  • LPL Financial sold 5,378 Anika Therapeutics shares in Q1 2016, an estimated $207K.
  • LPL Financial first reported a position in Anika Therapeutics in Q4 2015 and held it in 1 quarter.
  • LPL Financial's Anika Therapeutics position peaked at $207K in Q4 2015.
  • 162 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2016.

Based on LPL Financial's 13F filing for Q1 2016, filed 16 May 2016.